Results 21 to 30 of about 4,171 (132)

Reference levels for glucose-6-phosphate dehydrogenase enzyme activity in infants 7–90 days old in Taiwan

Journal of the Formosan Medical Association, 2020
Background: Nationwide newborn screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency has been implemented in Taiwan since 1987 and the G6PD enzyme activity levels were applied for diagnosis confirmation.
Wen-Chien Yang, Shin Tai, Chu-Ling Hsu, Chun-Min Fu, An-Kuo Chou, Pei-Lan Shao, Meng-Ju Li   +6 more
doaj   +1 more source

Distribution of G6PD deficiency genotypes among Southeast Asian populations

Tropical Medicine and Health, 2021
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a group of X-linked, hereditary genetic disorders caused by mutations in the G6PD gene and results in functional variants of about 400 biochemical and clinical phenotypes.
Indah S. Tantular, Fumihiko Kawamoto
doaj   +1 more source

Molecular characterization of G6PD mutations identifies new mutations and a high frequency of intronic variants in Thai females.

PLoS ONE, 2023
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked enzymopathy caused by mutations in the G6PD gene. A medical concern associated with G6PD deficiency is acute hemolytic anemia induced by certain foods, drugs, and infections.
Kamonwan Chamchoy, Sirapapha Sudsumrit, Jutamas Wongwigkan, Songsak Petmitr, Duantida Songdej, Emily R Adams, Thomas Edwards, Ubolsree Leartsakulpanich, Usa Boonyuen   +8 more
doaj   +1 more source

A fluorometric assay to determine the protective effect of glucose-6-phosphate dehydrogenase (G6PD) against a Plasmodium spp. infection in females heterozygous for the G6PD gene: proof of concept in Plasmodium falciparum

BMC Research Notes, 2022
Objective Glucose-6-phosphate dehydrogenase (G6PD) deficiency offers some protection against malaria; however, the degree of protection is poorly described and likely to vary with G6PD genotype and Plasmodium species.
Angela Rumaseb, Jutta Marfurt, Steven Kho, Maria Kahn, Ric N. Price, Benedikt Ley   +5 more
doaj   +1 more source

Primaquine-induced haemolysis in females heterozygous for G6PD deficiency

Malaria Journal, 2018
Oxidative agents can cause acute haemolytic anaemia in persons with G6PD deficiency. Understanding the relationship between G6PD genotype and the phenotypic expression of the enzyme deficiency is necessary so that severe haemolysis can be avoided.
Cindy S. Chu, Germana Bancone, François Nosten, Nicholas J. White, Lucio Luzzatto   +4 more
doaj   +1 more source

An update on glucose-6-phosphate dehydrogenase deficiency in children from Brazzaville, Republic of Congo

Malaria Journal, 2019
Background Malaria transmission-blocking anti-malarial drugs, such as primaquine, offers an effective strategy for reducing the incidence of falciparum malaria.
Nerly Shirère Gampio Gueye, Simon Marie Peko, David Nderu, Felix Koukouikila-Koussounda, Christevy Vouvoungui, Simon Charles Kobawila, Thirumalaisamy P. Velavan, Francine Ntoumi   +7 more
doaj   +1 more source

Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants. [PDF]

PLoS ONE, 2015
Chlorproguanil-dapsone (CD) has been linked to hemolysis in symptomatic glucose-6-phosphate dehydrogenase deficient (G6PDd) children. Few studies have explored the effects of G6PD status on hemolysis in children treated with Intermittent Preventive ...
Eugenie Poirot, Eric Vittinghoff, Deus Ishengoma, Michael Alifrangis, Ilona Carneiro, Ramadhan Hashim, Vito Baraka, Jacklin Mosha, Samwel Gesase, Daniel Chandramohan, Roland Gosling   +10 more
doaj   +1 more source

Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe malarial anaemia

eLife, 2017
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is believed to confer protection against Plasmodium falciparum malaria, but the precise nature of the protective effect has proved difficult to define as G6PD deficiency has multiple allelic variants ...
Geraldine M Clarke, Kirk Rockett, Katja Kivinen, Christina Hubbart, Anna E Jeffreys, Kate Rowlands, Muminatou Jallow, David J Conway, Kalifa A Bojang, Margaret Pinder, Stanley Usen, Fatoumatta Sisay-Joof, Giorgio Sirugo, Ousmane Toure, Mahamadou A Thera, Salimata Konate, Sibiry Sissoko, Amadou Niangaly, Belco Poudiougou, Valentina D Mangano, Edith C Bougouma, Sodiomon B Sirima, David Modiano, Lucas N Amenga-Etego, Anita Ghansah, Kwadwo A Koram, Michael D Wilson, Anthony Enimil, Jennifer Evans, Olukemi K Amodu, Subulade Olaniyan, Tobias Apinjoh, Regina Mugri, Andre Ndi, Carolyne M Ndila, Sophie Uyoga, Alexander Macharia, Norbert Peshu, Thomas N Williams, Alphaxard Manjurano, Nuno Sepúlveda, Taane G Clark, Eleanor Riley, Chris Drakeley, Hugh Reyburn, Vysaul Nyirongo, David Kachala, Malcolm Molyneux, Sarah J Dunstan, Nguyen Hoan Phu, Nguyen Ngoc Quyen, Cao Quang Thai, Tran Tinh Hien, Laurens Manning, Moses Laman, Peter Siba, Harin Karunajeewa, Steve Allen, Angela Allen, Timothy ME Davis, Pascal Michon, Ivo Mueller, Síle F Molloy, Susana Campino, Angeliki Kerasidou, Victoria J Cornelius, Lee Hart, Shivang S Shah, Gavin Band, Chris CA Spencer, Tsiri Agbenyega, Eric Achidi, Ogobara K Doumbo, Jeremy Farrar, Kevin Marsh, Terrie Taylor, Dominic P Kwiatkowski, MalariaGEN Consortium   +77 more
doaj   +1 more source

Optimizing G6PD testing for Plasmodium vivax case management and beyond: why sex, counseling, and community engagement matter [version 2; peer review: 2 approved]

Wellcome Open Research, 2020
Safe access to the most effective treatment options for Plasmodium vivax malaria are limited by the absence of accurate point-of-care testing to detect glucose-6-phosphate dehydrogenase (G6PD) deficiency, the most common human genetic disorder.
Cindy S Chu, Germana Bancone, Maureen Kelley, Nicole Advani, Gonzalo J Domingo, Eva M Cutiongo-de la Paz, Nicole van der Merwe, Jessica Cohen, Emily Gerth-Guyette   +8 more
doaj   +1 more source

Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.

PLoS Neglected Tropical Diseases, 2022
BackgroundPrimaquine and tafenoquine are the only licensed drugs that effectively kill the hypnozoite stage and are used to prevent Plasmodium vivax malaria relapse.
Kamonwan Chamchoy, Sirapapha Sudsumrit, Thanyapit Thita, Srivicha Krudsood, Rapatbhorn Patrapuvich, Usa Boonyuen   +5 more
doaj   +1 more source